N/A N=30 The Effect of Platelet Rich Plasma on Non-scarring Alopecia
Androgenetic Alopecia · Alopecia
Primary: Number of Participants With Improvement — 8; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=10 Randomized, Double-blind, Placebo-Controlled Pilot Study of MDMA-assisted Therapy for PTSD
Posttraumatic Stress Disorder (PTSD)
Primary: Change in Clinical Administered PTSD Scale (CAPS-IV) Total Score From Baseline to End of Stage 1 — -42.0; -9.0; -34.6 score on a scale
Phase 4 N=84 Tranexamic Acid Dosing for Total Joint Arthroplasty
Arthropathy of Hip · Arthropathy of Knee
Primary: Change in Hemoglobin From Baseline to the First Post-operative Day (POD#1) — 2.15; 2.06; 2.11 g/dl
Phase 3 N=589 Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
Actinic Keratosis
Primary: Number of Participants With Treatment Success/Failure at Visit 5/Week 14 — 42; 40; 6; 136 Participants
N/A N=199 Intensive Versus Standard Blood Pressure Lowering to Prevent Functional Decline in Older People
Hypertension, Systolic · Cerebrovascular Disease
Primary: Mobility - Measured by Change in Gait Speed — 0.4; 0.42 seconds
N/A N=34 Preoxygenation With Optiflow™ - the Effect of Speech on Lung Oxygenation.
Unrecognized Condition
Primary: End Tidal Oxygen Fraction — 43.9; 81.9 percentage of End-Tidal Oxygen Fraction
N/A N=11 Magnetic Correction of Eye Lid Paralysis
Blepharoptosis · Lagophthalmos · Facial Paralysis
Primary: Rating Scale of Skin Integrity — 0.3 units on a scale
Phase 2 N=286 Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease
Elevated Lipoprotein(a) · Cardiovascular Disease
Primary: Percent Change From Baseline in Fasting Lipoprotein A [Lp(a)] at the Primary Analysis Time Point — -35; -56; -72; -58 percent change — p=0.0032
Phase 2 N=1 Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100
Fanconi Anemia
Primary: Number of Participants Who Safely Received AMD3100 Used in Combination With Standard Dose G-CSF — 1 participants
Phase 2 N=20 Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin
Advanced Digestive System Neuroendocrine Neoplasm · Duodenal Neuroendocrine Tumor G1 · Functional Pancreatic Neuroendocrine Tumor
Primary: Number of Participants With Response Rate Per Response Evaluation Criteria in Solid Tumors Version 1.1 — 19 participants
Phase 3 N=226 54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide
Depressive Disorder, Major
Primary: Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score at 24 Hours After the First Dose (Day 2) (Last Observation Carried Forward [LOCF]…
N/A N=102 Clinical Investigation of New CI Delivery Models in an Adult Nucleus CI Population
Sensorineural Hearing Loss, Bilateral · Cochlear Implant
Primary: Change in Monosyllabic Word Recognition Scores (CNC) in Quiet — 13.9; 60.1; 60.2; 59.1 percentage of correct words
Phase 2 N=56 Study of Vorinostat (MK-0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL), or Mantle Cell Lymphoma (MCL) Participants (MK-0683-103)
Lymphoma
Primary: Objective Response Rate (ORR) — 48.7; 27.3 Percentage of participants
Phase 4 N=72 Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy
Heart Failure
Primary: Safety Endpoint: % of Patients With Non-surgical Bleeding at 6 Months Post HeartMate II Implant — 12; 15 Participants
N/A N=59 Randomized Trial of Y Mesh vs Dual Mesh
Prolapse
Primary: Total Suturing Time for Mesh Placement = Time From Insertion of Y Mesh or First Flat Mesh Arm Into Pelvis to Last Sacral Suture Placed — 46; 46.3 minutes